Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 6Melanoma 5Clear-cell metastatic renal cell carcinoma 4Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sjogren's Syndrome 1Scleroderma, Systemic 1Psoriasis 1Prostatic Neoplasms 1Penile Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Sclerosis 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lupus Erythematosus, Systemic 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Inflammatory Bowel Diseases 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Endometrial Neoplasms 1

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2pembrolizumab 1enfortumab vedotin 1cabozantinib 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Urachal adenocarcinoma × CTLA-4 Antigen × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡